The agreement follows Agilent’s acquisition of Canada-based CDMO BIOVECTRA in July 2024.
Author - David Miller
How to Enhance DEI in Clinical Trials
Integrating DEI strategies into clinical trials is both crucial for advancing biomedical knowledge...
Advantages & Disadvantages of Using Compounded Medications
Scott Brunner, CEO, and Tenille Davis, Chief Advocacy Officer, of the Alliance for Pharmacy...
Merck Agrees to Terms to Acquire Modifi Biosciences
Under terms of the deal, Merck will provide an upfront payment of $30 million, with potential...
FDA Approves Pfizer’s RSV Vaccine for Adults 18-59
Abrysvo had previously been approved for adults 60-years and older.
The Impact of Artificial Intelligence on the Creation of...
Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director...
Retrofitting Facilities for Cell and Gene Therapy Production
In this episode of the Ask the Expert video series, Peter Walters, Fellow of Advanced Therapies at...
Behind the Headlines: GLP-1 Shortage, Nobel Prize, RNA Editing...
Laks Pernenkil, Brian Feth, and Alex Philippidis go behind the headlines to discuss the impact of...
Identifying Illicit Actors vs Compound Pharmacies
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, explains how to identify a compound...
Pharma Pulse 10/25/24: Improving Site-Sponsor Collaboration...
The latest news for pharma industry insiders.